Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway-Reference-Cited by-同舟云学术

Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway

Published:2005-12 Issue:10 Volume:210 Page:775-780
ISSN:0171-2985
Container-title:Immunobiology
language:en
Short-container-title:Immunobiology

Author:

Yasuda Shinsuke,Bohgaki Miyuki,Atsumi Tatsuya,Koike Takao

Publisher

Elsevier BV

Subject

Hematology,Immunology,Immunology and Allergy

Reference40 articles.

1. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome;Amengual;Thromb. Haemost.,1998

2. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies – a crucial role for acquired free protein S deficiency;Ames;Thromb. Haemost.,1996

3. Up-regulated tissue factor expression in antiphospholipid syndrome;Atsumi;Thromb. Haemost.,1997

4. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome;Atsumi;J. Rheumatol.,1998

5. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2Glycoprotein I antibodies;Bohgaki;Int. Immunol.,2004

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-phospholipid autoantibodies in human diseases;Clinical Immunology;2023-11

2. The role of monocytes in thrombotic diseases: a review;Frontiers in Cardiovascular Medicine;2023-06-02

3. The interaction of persistent antiphospholipid antibodies positivity and cigarette smoking is associated with an increased risk of cardiovascular events: Cross-sectional and longitudinal analysis;International Journal of Cardiology;2023-03

4. Tissue factor in COVID-19-associated coagulopathy;Thrombosis Research;2022-12

5. Emerging Therapies in Antiphospholipid Syndrome;Transfusion Medicine Reviews;2022-10